This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ohtsu, A. Articles by Nakamura, A. Search for Related Content PubMed PubMed Citation Articles by Ohtsu, A. Articles by Nakamura, A. Social Bookmarking                            What's this?

Definitive Chemoradiotherapy for T4 and/or M1 Lymph Node Squamous Cell Carcinoma of the Esophagus

From the Departments of Gastrointestinal Oncology/Gastroenterology and Radiation Oncology, National Cancer Center Hospital East, Kashiwa; Department of Internal Medicine, Saku Central Hospital, Nagano; Second Department of Internal Medicine, Showa University Hospital, Tokyo; and Department of Internal Medicine, Asahi Central Hospital, Asahi, Japan.

Address reprint requests to Atsushi Ohtsu, MD, Department of Gastrointestinal Oncology/Gastroenterology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577 Japan; email aohtsu{at}east.ncc.go.jp

PURPOSE: To investigate the efficacy and feasibility of concurrent chemoradiotherapy for locally advanced carcinoma of the esophagus.

PATIENTS AND METHODS: Fifty-four patients with clinically T4 and/or M1 lymph node (LYM) squamous cell carcinoma of the esophagus were enrolled. Patients received protracted infusion of fluorouracil 400 mg/m²/24 hours on days 1 to 5 and 8 to 12, 2-hour infusion of cisplatin 40 mg/m² on days 1 and 8, and concurrent radiation therapy at a dose of 30 Gy in 15 fractions over 3 weeks. Filgrastim was prophylactically administered to 35 patients. This schedule was repeated twice every 5 weeks, for a total radiation dose of 60 Gy, followed by two courses of fluorouracil (800 mg/m²/24 hours for 5 days) and cisplatin (80 mg/m² on day 1).

RESULTS: There were 21 patients with T4M0 disease, one with T2M1 LYM, 17 with T3M1 LYM, and 15 withT4M1 LYM. Forty-nine patients (91%) completed at least the chemoradiotherapy segment. The 18 patients (33%) who achieved a complete response included nine (25%) of the 36 with T4 disease and nine (50%) of the 18 with non-T4 disease. Major toxicities were leukocytopenia and esophagitis; there were four (7%) treatment-related deaths. Prophylactic filgrastim reduced the incidence of grade 3 or worse leukopenia without improving dose-intensity or response. With a median follow-up duration of 43 months, median survival time was 9 months. The 3-year survival rate was 23%.

CONCLUSION: Despite its significant toxicity, this combined modality seemed to have curative potential even in cases of locally advanced carcinoma of the esophagus.

Presented in part at the Thirty-Fourth Annual Meeting of the American Society of Clinical Oncology, Los Angeles, CA, May 18, 1998.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Yamaguchi, K. Tobinai, M. Oguchi, N. Ishizuka, Y. Kobayashi, Y. Isobe, K. Ishizawa, N. Maseki, K. Itoh, N. Usui, et al. Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211 J. Clin. Oncol., November 20, 2009; 27(33): 5594 - 5600. [Abstract] [Full Text] [PDF]

				H. Kato, A. Sato, H. Fukuda, Y. Kagami, H. Udagawa, A. Togo, N. Ando, O. Tanaka, M. Shinoda, H. Yamana, et al. A Phase II Trial of Chemoradiotherapy for Stage I Esophageal Squamous Cell Carcinoma: Japan Clinical Oncology Group Study (JCOG9708) Jpn. J. Clin. Oncol., October 1, 2009; 39(10): 638 - 643. [Abstract] [Full Text] [PDF]

				Y. Kurokawa, M. Muto, K. Minashi, N. Boku, H. Fukuda, and for the Gastrointestinal Oncology Study Group of J A Phase II Trial of Combined Treatment of Endoscopic Mucosal Resection and Chemoradiotherapy for Clinical Stage I Esophageal Carcinoma: Japan Clinical Oncology Group Study JCOG0508 Jpn. J. Clin. Oncol., October 1, 2009; 39(10): 686 - 689. [Abstract] [Full Text] [PDF]

				Y. Tachimori, N. Kanamori, N. Uemura, N. Hokamura, H. Igaki, and H. Kato Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma. J. Thorac. Cardiovasc. Surg., January 1, 2009; 137(1): 49 - 54. [Abstract] [Full Text] [PDF]

				Y. Yamabe, Y. Kuroki, T. Ishikawa, K. Miyakawa, S. Kuroki, and R. Sekiguchi Tumor Staging of Advanced Esophageal Cancer: Combination of Double-Contrast Esophagography and Contrast-Enhanced CT Am. J. Roentgenol., September 1, 2008; 191(3): 753 - 757. [Abstract] [Full Text] [PDF]

				S. S. Lee, S.-B. Kim, S.-I. Park, Y. H. Kim, J.-S. Ryu, H.-Y. Song, J. H. Shin, H. Y. Jung, G. H. Lee, K. D. Choi, et al. Capecitabine and Cisplatin Chemotherapy (XP) Alone or Sequentially Combined Chemoradiotherapy Containing XP Regimen in Patients with Three Different Settings of Stage IV Esophageal Cancer Jpn. J. Clin. Oncol., November 1, 2007; 37(11): 829 - 835. [Abstract] [Full Text] [PDF]

				M. Gotoh, H. Takiuchi, S.-i. Kawabe, S. Ohta, T. Kii, S. Kuwakado, and K.-i. Katsu Epidermal Growth Factor Receptor is a Possible Predictor of Sensitivity to Chemoradiotherapy in the Primary Lesion of Esophageal Squamous Cell Carcinoma Jpn. J. Clin. Oncol., September 1, 2007; 37(9): 652 - 657. [Abstract] [Full Text] [PDF]

				T. Kii, H. Takiuchi, S. Kawabe, M. Gotoh, S. Ohta, T. Tanaka, S. Kuwakado, H. Nishitani, and K.-i. Katsu Evaluation of Prognostic Factors of Esophageal Squamous Cell Carcinoma (Stage II III) After Concurrent Chemoradiotherapy Using Biopsy Specimens Jpn. J. Clin. Oncol., August 20, 2007; (2007) hym077v1. [Abstract] [Full Text] [PDF]

				Y. Murakami, M. Kenjo, T. Uno, M. Oguchi, M. Shimada, T. Teshima, and the Japanese Patterns of Care Study Working Subgro Results of the 1999 2001 Japanese Patterns of Care Study for Patients Receiving Definitive Radiation Therapy without Surgery for Esophageal Cancer Jpn. J. Clin. Oncol., July 23, 2007; (2007) hym055v1. [Abstract] [Full Text] [PDF]

				G. de Manzoni, C. Pedrazzani, E. Laterza, F. Pasini, A. Grandinetti, M. Bernini, A. Ruzzenente, G. Zerman, A. Tomezzoli, and C. Cordiano Induction Chemoradiotherapy for Squamous Cell Carcinoma of the Thoracic Esophagus: Impact of Increased Dosage on Long-Term Results Ann. Thorac. Surg., October 1, 2005; 80(4): 1176 - 1183. [Abstract] [Full Text] [PDF]

				M. Tahara, A. Ohtsu, S. Hironaka, N. Boku, S. Ishikura, Y. Miyata, T. Ogino, and S. Yoshida Clinical Impact of Criteria for Complete Response (CR) of Primary Site to Treatment of Esophageal Cancer Jpn. J. Clin. Oncol., June 1, 2005; 35(6): 316 - 323. [Abstract] [Full Text] [PDF]

				K. Ishida, N. Ando, S. Yamamoto, H. Ide, and M. Shinoda Phase II Study of Cisplatin and 5-Fluorouracil with Concurrent Radiotherapy in Advanced Squamous Cell Carcinoma of the Esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group Trial (JCOG9516) Jpn. J. Clin. Oncol., October 1, 2004; 34(10): 615 - 619. [Abstract] [Full Text] [PDF]

				S. Ishikura, K. Nihei, A. Ohtsu, N. Boku, S. Hironaka, K. Mera, M. Muto, T. Ogino, and S. Yoshida Long-Term Toxicity After Definitive Chemoradiotherapy for Squamous Cell Carcinoma of the Thoracic Esophagus J. Clin. Oncol., July 15, 2003; 21(14): 2697 - 2702. [Abstract] [Full Text] [PDF]

				Y. Nishimura, R. Koike, K. Nakamatsu, S. Kanamori, M. Suzuki, H. Shigeoka, and H. Shiozaki Concurrent Chemoradiotherapy with Protracted Infusion of 5-FU and Cisplatin for Postoperative Recurrent or Residual Esophageal Cancer Jpn. J. Clin. Oncol., July 1, 2003; 33(7): 341 - 345. [Abstract] [Full Text] [PDF]

				M. Morihiro, N. Boku, A. Ohtsu, S.'i. Miyamoto, and S. Ishikura Advanced Esophageal Cancer with Esophago-bronchial Fistula Successfully Treated by Chemoradiation Therapy with Additional Endoscopic Resection: a Case Report Jpn. J. Clin. Oncol., February 1, 2002; 32(2): 59 - 63. [Abstract] [Full Text] [PDF]

				S. Hironaka, T. Hasebe, T. Kamijo, A. Ohtsu, N. Boku, S. Yoshida, H. Saitoh, and A. Ochiai Biopsy Specimen Microvessel Density Is a Useful Prognostic Marker in Patients with T2-4M0 Esophageal Cancer Treated with Chemoradiotherapy Clin. Cancer Res., January 1, 2002; 8(1): 124 - 130. [Abstract] [Full Text] [PDF]

				T. Toita, K. Ogawa, G. Adachi, Y. Kakinohana, Y. Nishikuramori, S. Iraha, T. Utsunomiya, and S. Murayama Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Thoracic Esophagus: Feasibility and Outcome of Large Regional Field and High-dose External Beam Boost Irradiation Jpn. J. Clin. Oncol., August 1, 2001; 31(8): 375 - 381. [Abstract] [Full Text] [PDF]

				N Fuwa, Y Nomoto, K Shouji, T Kodaira, M Kamata, and Y Ito Therapeutic effects of simultaneous intraluminal irradiation and intraluminal hyperthermia on oesophageal carcinoma Br. J. Radiol., August 1, 2001; 74(884): 709 - 714. [Abstract] [Full Text] [PDF]

				M. Muto, A. Ohtsu, Y. Miyata, Y. Shioyama, N. Boku, and S. Yoshida Self-expandable Metallic Stents for Patients with Recurrent Esophageal Carcinoma After Failure of Primary Chemoradiotherapy Jpn. J. Clin. Oncol., June 1, 2001; 31(6): 270 - 274. [Abstract] [Full Text] [PDF]

				W. Fang, H. Kato, W. Chen, Y. Tachimori, H. Igaki, and H. Sato Comparison of Surgical Management of Thoracic Esophageal Carcinoma Between Two Referral Centers in Japan and China Jpn. J. Clin. Oncol., May 1, 2001; 31(5): 203 - 208. [Abstract] [Full Text] [PDF]